Aclaris Therapeutics, Inc. (ACRS)
5.965
-0.20
(-3.17%)
USD |
NASDAQ |
Aug 28, 13:02
Aclaris Therapeutics Cash from Operations (Quarterly) : -19.85M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -19.85M |
| March 31, 2026 | -18.15M |
| December 31, 2025 | -13.13M |
| September 30, 2025 | -10.93M |
| June 30, 2025 | -9.993M |
| March 31, 2025 | -13.06M |
| December 31, 2024 | -8.938M |
| September 30, 2024 | 22.00M |
| June 30, 2024 | -12.32M |
| March 31, 2024 | -20.82M |
| December 31, 2023 | -6.761M |
| September 30, 2023 | -24.56M |
| June 30, 2023 | -20.65M |
| March 31, 2023 | -26.35M |
| December 31, 2022 | -19.12M |
| September 30, 2022 | -7.817M |
| June 30, 2022 | -19.67M |
| March 31, 2022 | -20.97M |
| December 31, 2021 | -17.08M |
| September 30, 2021 | -10.61M |
| June 30, 2021 | -12.22M |
| March 31, 2021 | -12.23M |
| Date | Value |
|---|---|
| December 31, 2020 | -8.857M |
| September 30, 2020 | -12.15M |
| June 30, 2020 | -10.82M |
| March 31, 2020 | -6.805M |
| December 31, 2019 | -20.39M |
| September 30, 2019 | -23.36M |
| June 30, 2019 | -21.38M |
| March 31, 2019 | -31.32M |
| December 31, 2018 | -27.25M |
| September 30, 2018 | -29.86M |
| June 30, 2018 | -21.83M |
| March 31, 2018 | -21.87M |
| December 31, 2017 | -18.21M |
| September 30, 2017 | -13.71M |
| June 30, 2017 | -10.08M |
| March 31, 2017 | -12.66M |
| December 31, 2016 | -8.072M |
| September 30, 2016 | -9.905M |
| June 30, 2016 | -9.732M |
| March 31, 2016 | -6.894M |
| December 31, 2015 | -4.137M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 33.54M |
| Nektar Therapeutics | -75.77M |
| Xeris Biopharma Holdings, Inc. | 8.263M |
| Crinetics Pharmaceuticals, Inc. | -94.19M |
| Alumis, Inc. | -81.50M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 10.26M |
| Cash from Financing (Quarterly) | 0.091M |
| Free Cash Flow | -61.34M |
| Free Cash Flow Per Share (Quarterly) | -0.1395 |
| Free Cash Flow to Equity (Quarterly) | -19.77M |
| Free Cash Flow to Firm (Quarterly) | -19.90M |
| Free Cash Flow Yield | -7.96% |